Companies › Joincare Pharmaceutical Group Industry
4 active drug programs in 4 registered trials: 2 Phase 2, 1 Phase 1, 1 Phase 3; Respiratory, Infectious disease.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JKN2301 Dry Suspension Neuraminidase inhibitor | – | Phase 3 | Respiratory Viral Infection | – |
| JKN24011 | – | Phase 2 | COPD (Chronic Obstructive Pulmonary Disease) | – |
| JKN2403 | – | Phase 2 | COPD (Chronic Obstructive Pulmonary Disease) | – |
| JKN2501 | – | Phase 1 | Bacterial Infections | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07357051 | JKN2301 Dry Suspension | Phase 3 | Respiratory Viral Infection | Infectious disease | Jan 2026 |
| NCT07207291 | JKN2501 | Phase 1 | Bacterial Infections | Infectious disease | Mar 2026 |
| NCT07440524 | JKN24011 | Phase 2 | COPD (Chronic Obstructive Pulmonary Disease) | Respiratory | Apr 2026 |
| NCT07351734 | JKN2403 | Phase 2 | COPD (Chronic Obstructive Pulmonary Disease) | Respiratory | Sep 2026 |
No annotated target.
–
Mundipharma Research Thirty Respiratory Materia Medica Holding Shanghai Yidian Pharmaceutical Technology Development VivaVision Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.